Did you know NCI has one of the largest SBIR and STTR programs in the United States? In 2018, the NCI SBIR Development Center conducted an economic impact study to help quantify the program’s overall contribution to the national economy.
The study examined the economic outcomes and impacts leading up to 2018 from all NCI SBIR/STTR Phase II awards initiated from FY 1998 to FY 2010. A total of 444 companies received Phase II funding for 690 separate projects over the period.
The following major findings quantify the achievements of SBIR-funded small businesses nationwide:
Other economic outcomes include:
- Total outside investment funding: $4.26 billion
- Total acquisition value of companies acquired: $21.63 billion
For more information about the NCI SBIR Economic Impact Study, please see the study brief or the full report.
NCI SBIR State Level Impact Analysis
Are you looking for a deeper dive into NCI cancer tech startup impact across the country?
A state-level breakout of the economic results of the NCI SBIR/STTR program was also conducted for the top fifteen individual states that are home to the greatest numbers of successful SBIR/STTR companies. (The District of Columbia is treated as a state for this purpose.)
Each of the fifteen states profiled below had a minimum of eight companies reporting commercialized products during the analysis. States with fewer than eight successful companies in the study's timeframe were not included in order to ensure the confidentiality of individual companies' award outcomes.
Click the links below to explore the economic impact NCI SBIR- and STTR-funded small business generate in these states.
CALIFORNIA: $9.3 BILLION IN TOTAL ECONOMIC IMPACT
One NCI SBIR-funded company reported over $3.5 billion in revenue from the project our program supported. Click to learn more about this startup's success and SBIR/STTR impact in California.
MASSACHUSETTS: $1.6 BILLION IN TOTAL ECONOMIC IMPACT
NCI SBIR- and STTR-awarded small businesses in Massachusetts reported $629.1 million in total sales as a result of Phase II awards. Click to discover the results our program has achieved in the Bay State.
TEXAS: $1.4 BILLION IN TOTAL ECONOMIC IMPACT
Over 5,000 jobs were created by Phase II NCI SBIR- and STTR-awarded companies in Texas. Click to learn more about how non-dilutive funding from the NCI helps shape the state’s economy.
PENNSYLVANIA: $1.3 BILLION IN TOTAL ECONOMIC IMPACT
A Pennsylvania small business that received NCI SBIR/STTR funding completed a $438 million acquisition agreement in 2021. Click to view more on the results our program helped cancer technology innovators achieve in the Keystone State.
NEW YORK: $1.1 BILLION IN TOTAL ECONOMIC IMPACT
New York NCI SBIR/STTR cancer technology startups created 4,200 jobs. Click to view success stories and additional outcomes from our program’s support to innovators in the Empire State.
WASHINGTON: $947 MILLION IN TOTAL ECONOMIC IMPACT
SBIR- and STTR-funded biotech startups in Washington state saw their products generate $425.5 million in total direct sales. Click to find out how else NCI support made a difference for entrepreneurs in this state.
WISCONSIN: $785 MILLION IN TOTAL ECONOMIC IMPACT
Did you know that approximately 4,300 jobs were created by Wisconsin-based companies that received Phase II NCI SBIR/STTR awards? Click to further explore the financial milestones of cancer technology innovators in the state.
ILLINOIS: $582.2 MILLION IN TOTAL ECONOMIC IMPACT
An NCI SBIR-awarded startup based in Illinois completed a $140 million acquisition agreement in 2022. Click to view this success story and SBIR/STTR impact in the Prairie State.
NORTH CAROLINA: $499.3 MILLION IN TOTAL ECONOMIC IMPACT
Phase II NCI SBIR/STTR grantees in North Carolina helped drive $123.1 million in total direct sales from their cancer technologies. Click to learn more about NCI SBIR impact in North Carolina.
MARYLAND: $444.3 MILLION IN TOTAL ECONOMIC IMPACT
$139.1 million in total direct sales of cancer technologies resulted from SBIR/STTR awardees in Maryland. Click to see more about the financial contributions of NCI-funded small businesses in the Old Line State.
MICHIGAN: $417.1 MILLION IN TOTAL ECONOMIC IMPACT
In Michigan, technologies that were developed with the support of SBIR/STTR funding generated 2,100 jobs. Click to receive further details into the economic developments made by NCI supported biotech entrepreneurs.
VIRGINIA: $349.1 MILLION IN TOTAL ECONOMIC IMPACT
When bolstered with NCI SBIR/STTR support, biotech entrepreneurs in Virginia added 1,500 jobs. Click to find out more about the impact our program had on the state’s economy.
NEW JERSEY: $344.7 MILLION IN TOTAL ECONOMIC IMPACT
New Jersey-based startups funded by NCI created 1,500 jobs in association with their SBIR/STTR projects. Click to delve into additional economic outcomes from non-dilutive funding in the Garden State.
COLORADO: $195.8 MILLION IN TOTAL ECONOMIC IMPACT
Rocky Mountain innovation from SBIR- and STTR-funded small businesses in Colorado produced $21.5 million in total direct sales of their commercialized products. Click to take a closer look at the achievements of NCI awardees in the state.
WASHINGTON, D.C.: $85.3 MILLION IN TOTAL ECONOMIC IMPACT
The efforts of NCI SBIR- and STTR-awarded innovators in Washington, D.C led to $20.2 million in total direct sales of their cancer technologies. Click to gain a deeper understanding of our program’s impact in the nation’s capital.